Market closedNon-fractionalADR
Mereo BioPharma Group/MREO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Mereo BioPharma Group
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Ticker
MREO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
London, United Kingdom
Employees
36
Website
www.mereobiopharma.com
MREO Metrics
BasicAdvanced
$484M
Market cap
-
P/E ratio
-$0.27
EPS
0.71
Beta
-
Dividend rate
Price and volume
Market cap
$484M
Beta
0.71
52-week high
$4.36
52-week low
$1.00
Average daily volume
21
Financial strength
Current ratio
3.106
Long term debt to equity
8.032
Total debt to equity
16.126
Management effectiveness
Return on assets (TTM)
-27.63%
Return on equity (TTM)
-40.95%
Return on investment (TTM)
-38.33%
Valuation
Price to revenue (TTM)
53.295
Price to book
6.033
Price to tangible book (TTM)
11.547
Growth
Earnings per share change (TTM)
-31.83%
What the Analysts think about MREO
Analyst Ratings
Majority rating from 4 analysts.
MREO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
£7.1M
∞%
Net income
-£11M
-26.67%
Profit margin
-154.92%
-∞%
MREO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Actual
-
Expected
-£0.00
Surprise
-
MREO News
AllArticlesVideos
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
GlobeNewsWire·1 month ago
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $484M as of July 27, 2024.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of July 27, 2024.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Mereo BioPharma Group stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.